Neuphoria has completed the re-domiciliation process with Bionomics Limited, becoming the parent company on Nasdaq.
Neuphoria Therapeutics Inc., listed as NEUP on Nasdaq, has successfully completed the scheme of arrangement to facilitate Bionomics Limited's move from Australia to the United States. Neuphoria will now act as the primary parent company for Bionomics Limited, with the implementation taking place on December 23, 2024 in New York and December 24, 2024 in Sydney. This move marks a significant transition in the structures of both companies, representing a strategic shift in their operations.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments